| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029334059 |
| P356 | DOI | 10.1038/LEU.2010.163 |
| P953 | full work available at URL | https://www.nature.com/articles/leu2010163.pdf |
| https://www.nature.com/articles/leu2010163 | ||
| P698 | PubMed publication ID | 20724988 |
| P5875 | ResearchGate publication ID | 45721330 |
| P50 | author | Ayalew Tefferi | Q66370740 |
| P2093 | author name string | S. T. Oh | |
| C. Finke | |||
| A. Pardanani | |||
| T. Lasho | |||
| J. Gotlib | |||
| P2860 | cites work | Journal of Clinical Investigation | Q3186904 |
| The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 | ||
| Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways | Q28306960 | ||
| Lnk constrains myeloproliferative diseases in mice | Q33882944 | ||
| Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. | Q34074931 | ||
| Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias | Q34162729 | ||
| TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis | Q36303447 | ||
| Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis | Q36402414 | ||
| JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials | Q36946580 | ||
| Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal | Q37170349 | ||
| Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F | Q37232941 | ||
| Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders | Q41974528 | ||
| IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. | Q43089505 | ||
| MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 | ||
| Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. | Q51761197 | ||
| Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. | Q53544139 | ||
| The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. | Q54713883 | ||
| Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera | Q80258200 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1713-1718 | |
| P577 | publication date | 2010-08-19 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations | |
| P478 | volume | 24 |
| Q36005362 | 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells |
| Q90628971 | A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression |
| Q36907588 | A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis |
| Q34166859 | Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management |
| Q38014534 | BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques |
| Q26777265 | Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors |
| Q38844669 | Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches |
| Q35217865 | Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia |
| Q83640566 | Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations |
| Q33595912 | Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis |
| Q36776428 | Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. |
| Q27853179 | Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib |
| Q34302770 | Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms |
| Q92005886 | DLGAP1 directs megakaryocytic growth and differentiation in an MPL dependent manner in hematopoietic cells |
| Q37955142 | Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms |
| Q36174146 | Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia |
| Q38066786 | Genetic and epigenetic alterations of myeloproliferative disorders |
| Q26823651 | Genetics of myeloproliferative neoplasms |
| Q26770330 | Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis |
| Q26829976 | Genomic profiling of B-progenitor acute lymphoblastic leukemia |
| Q38046648 | Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms |
| Q35835653 | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F |
| Q34348505 | Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing |
| Q36842989 | Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities |
| Q42583762 | Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis |
| Q38127417 | Inherited predisposition to myeloproliferative neoplasms |
| Q33697252 | Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis |
| Q34150008 | JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations |
| Q26782539 | JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications |
| Q34641224 | JAK/STAT signaling in hematological malignancies. |
| Q34652224 | JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis |
| Q38044736 | JAK2 inhibitors in the treatment of myeloproliferative neoplasms. |
| Q37950581 | JAK2 inhibitors: are they the solution? |
| Q38667486 | LNK mutations and myeloproliferative disorders |
| Q64052024 | LNK suppresses interferon signaling in melanoma |
| Q37409325 | Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling |
| Q50860383 | Lnk prevents inflammatory CD8⁺ T-cell proliferation and contributes to intestinal homeostasis. |
| Q36366973 | Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow |
| Q38050756 | Molecular biology of Philadelphia-negative myeloproliferative neoplasms |
| Q37555785 | Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms |
| Q54518446 | Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. |
| Q43109584 | Mutational analysis of SH2B3 in Korean patients with BCR-ABL1 negative myeloproliferative neoplasm |
| Q54574818 | Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? |
| Q50072000 | Mutations in myeloproliferative neoplasms - their significance and clinical use. |
| Q27000577 | Myeloid malignancies: mutations, models and management |
| Q38046320 | Myeloproliferative neoplasm animal models |
| Q37877727 | Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? |
| Q38613880 | Myeloproliferative neoplasms: A decade of discoveries and treatment advances |
| Q34629928 | Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies |
| Q36909019 | Normal and malignant megakaryopoiesis |
| Q33997280 | Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis |
| Q26779960 | Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation |
| Q26799656 | Pathogenesis of myeloproliferative neoplasms |
| Q38926804 | Prognosis of Primary Myelofibrosis in the Genomic Era |
| Q38740198 | Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression |
| Q38046319 | Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms |
| Q38050407 | Role of the adaptor protein LNK in normal and malignant hematopoiesis |
| Q92528596 | Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation |
| Q38100790 | Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians |
| Q36901651 | SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. |
| Q33393587 | Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis |
| Q39083031 | Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. |
| Q36784523 | Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. |
| Q89776742 | Targeted deep sequencing in polycythemia vera and essential thrombocythemia |
| Q48302310 | Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms |
| Q36364763 | The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis |
| Q38044625 | The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis |
| Q35998214 | The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms |
| Q64085216 | The Role of New Technologies in Myeloproliferative Neoplasms |
| Q38683077 | The evolution and clinical relevance of prognostic classification systems in myelofibrosis |
| Q39292396 | The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders |
| Q28082685 | The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control |
| Q37968531 | Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? |
| Q44890063 | Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia |
| Q41418744 | Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium |
| Q42870230 | Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology |
| Q39788785 | When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms |
Search more.